Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azathioprine + prednisolone + tacrolimus
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination immunosuppressive regimen used primarily in solid organ transplantation to prevent rejection. This triple therapy combines different mechanisms of action:
- Tacrolimus inhibits calcineurin, preventing T-cell activation and proliferation
- Prednisolone is a corticosteroid that suppresses inflammation and immune response
- Azathioprine is an antimetabolite that interferes with DNA synthesis in rapidly dividing cells, including immune cells
This combination has been studied in various transplant settings including kidney, liver, and heart transplantation.
02
Targets
Beyond the preview
Go deeper on azathioprine + prednisolone + tacrolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azathioprine + prednisolone + tacrolimus.